[The National Comprehensive Cancer Network (NCCN) recently made news when it named the genomic/somatic test Decipher Prostate Genomic Classifier as the first test of its kind to be recognized as having high-level evidence of benefit. That seemed to me to give Decipher an edge in what I see as a competition for patients’ cores to be tested. I asked Decipher’s competitors, Myriad’s Prolaris, or Mdxhealth’s OncotypeDx GPS (Genomic Prostate Score), for comments.
Howard. Thanks for another fantastic article. I do have to admit that a lot of it is well over my head but it appears that Decipher is nt the best test for biopsy tissue. Of all the specialists I have talked too (5 total) not one suggested this. other than Randy Vincent who told me that I was not the intended target ( low volume Gleason 6) for his Decipher study. Stay well, Jamie
I am not sure that Dr. Toward accurately represented the effectiveness of using Oncotype DX as a predictive test for death at ten years and metastasis in ten years. My Oncotype DX test results provided a predictive score for both. I have used that scoring as a key element in decision making to remain on AS
Thanks, Jamie.
It is confusing. The docs can disagree.
Howard
Howard. Thanks for another fantastic article. I do have to admit that a lot of it is well over my head but it appears that Decipher is nt the best test for biopsy tissue. Of all the specialists I have talked too (5 total) not one suggested this. other than Randy Vincent who told me that I was not the intended target ( low volume Gleason 6) for his Decipher study. Stay well, Jamie
Thanks, Richard.
I'll ask Dr. Tward.
Howard
I am not sure that Dr. Toward accurately represented the effectiveness of using Oncotype DX as a predictive test for death at ten years and metastasis in ten years. My Oncotype DX test results provided a predictive score for both. I have used that scoring as a key element in decision making to remain on AS
Richard M.